MASCC — Febrile Neutropenia Risk Score
Burden of febrile neutropenia illness
Detailed Guide Coming Soon
We're working on a comprehensive educational guide for the Febrile Neutropenia MASCC Score. Check back soon for step-by-step explanations, formulas, real-world examples, and expert tips.
Febrile neutropenia (FN) is a common and potentially life-threatening complication of cancer chemotherapy, defined as a single oral temperature above 38.3°C or a temperature above 38.0°C sustained for more than one hour in a patient with an absolute neutrophil count (ANC) below 500 cells/µL or an ANC expected to fall below 500 cells/µL within 48 hours. FN requires immediate medical evaluation because neutropenic patients lack the ability to mount effective immune responses against bacterial and fungal pathogens, placing them at high risk of sepsis and death without prompt antibiotic therapy. Risk stratification at the time of FN presentation is critical for determining whether a patient can be managed with oral antibiotics at home or requires intravenous antibiotics and hospitalisation. The Multinational Association for Supportive Care in Cancer (MASCC) risk index is the most widely validated tool for this purpose. The MASCC score uses seven clinical variables: burden of illness (assessed by severity of FN signs and symptoms, 0–5 points), absence of hypotension (5 points), absence of chronic obstructive pulmonary disease (4 points), solid tumour or lymphoma without prior fungal infection (4 points), absence of dehydration (3 points), outpatient status at onset of fever (3 points), and age below 60 years (2 points). The maximum MASCC score is 26. A score of 21 or above identifies patients as low-risk — defined as those with less than 5% risk of serious medical complications — who may be candidates for oral antibiotic therapy (ciprofloxacin + amoxicillin-clavulanate) and early discharge or outpatient management. Patients with MASCC scores below 21 are classified as high-risk and require hospital admission and intravenous broad-spectrum antibiotics.
MASCC Score = points(burden of illness) + points(no hypotension) + points(no COPD) + points(solid tumour/lymphoma without prior fungal infection) + points(no dehydration) + points(outpatient at fever onset) + points(age < 60); Score ≥ 21 = low risk
- 1Assess burden of febrile illness at presentation: 5 points for no/mild symptoms, 3 points for moderate symptoms, 0 points for severe symptoms (the only variable where higher symptoms give lower score).
- 2Assess blood pressure: assign 5 points if systolic BP is ≥90 mmHg (no hypotension). Hypotension (SBP <90) scores 0 for this component.
- 3Assess for known chronic obstructive pulmonary disease (COPD) or active pulmonary disease: 4 points if the patient has no COPD or active chronic pulmonary disease.
- 4Assess tumour type and infection history: 4 points if the patient has a solid tumour or haematological malignancy without a prior fungal infection. Patients with prior documented invasive fungal infection or haematological malignancy with prior fungal disease score 0.
- 5Assess hydration status: 3 points if no significant dehydration requiring IV fluids. Dehydration requiring IV fluids scores 0.
- 6Assess onset setting: 3 points if the patient was an outpatient when the fever developed. Inpatient onset of fever scores 0.
- 7Assess age: 2 points if the patient is younger than 60 years. Age 60 or above scores 0. Sum all components. Score ≥21 = low risk (outpatient antibiotics may be appropriate); score <21 = high risk (hospitalise and administer IV antibiotics).
Suitable for oral ciprofloxacin + amoxicillin-clavulanate and discharge with 24-hour review
Maximum MASCC score indicates the patient has less than 5% risk of serious medical complications. Outpatient oral antibiotics with strict return precautions and a 24-hour telephone/clinic review is appropriate.
Immediate IV broad-spectrum antibiotics; ICU assessment; antifungal therapy likely needed
A MASCC score of 0 represents maximal clinical risk. This patient requires immediate empirical IV antibiotics (piperacillin-tazobactam or meropenem), likely antifungal cover, and intensive monitoring.
Score ≥21 suggests low risk, but age ≥60 with lymphoma warrants careful clinical assessment before discharge
While the MASCC score of 22 meets the low-risk threshold, the borderline score combined with age 62 and lymphoma diagnosis warrants careful clinical review, blood culture results, and close follow-up before confirming outpatient management.
Inpatient FN always requires IV antibiotics initially regardless of MASCC score; MASCC guides step-down to oral after 48h
Inpatient-onset FN should always be treated initially with IV antibiotics. A high MASCC score in this context supports early step-down to oral antibiotics after 48 hours of clinical stability.
Primary care physicians and internists use Febrile Neutropenia Risk during routine clinical assessments to screen patients, establish baselines for longitudinal monitoring, and identify individuals who may need referral to specialists for further diagnostic evaluation or therapeutic intervention.
Hospital clinical pharmacists apply Febrile Neutropenia Risk to verify drug dosing calculations, particularly for medications with narrow therapeutic indices like warfarin, aminoglycosides, and chemotherapy agents where patient-specific factors such as renal function and body weight critically affect safe dosing ranges.
Public health epidemiologists use Febrile Neutropenia Risk in population-level screening programs to calculate disease prevalence, assess screening test sensitivity and specificity, and determine the number needed to screen to detect one case in various demographic subgroups.
Clinical researchers incorporate Febrile Neutropenia Risk into study design protocols to calculate sample sizes, determine statistical power for detecting clinically meaningful differences, and establish inclusion criteria based on quantitative physiological thresholds.
Pediatric versus adult reference ranges
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in febrile neutropenia risk calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Pregnancy and hormonal variations
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in febrile neutropenia risk calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Extreme body composition
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in febrile neutropenia risk calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
FN in elderly cancer patients
Age 60 or above automatically excludes the 2-point MASCC age bonus, making it harder for elderly patients to reach the low-risk threshold of 21. Elderly patients also have more comorbidities and are more likely to decompensate rapidly, so caution is advised even if MASCC suggests low risk.
| Variable | Points | Scoring Criterion |
|---|---|---|
| Burden of illness — no/mild symptoms | 5 | Patient has no or only mild FN symptoms |
| Burden of illness — moderate symptoms | 3 | Patient has moderate FN-related symptoms |
| Burden of illness — severe symptoms | 0 | Patient has severe FN-related symptoms |
| No hypotension (SBP ≥ 90 mmHg) | 5 | Systolic BP ≥90 mmHg at presentation |
| No COPD | 4 | Patient has no chronic obstructive pulmonary disease |
| Solid tumour or lymphoma/no prior fungal | 4 | Solid tumour, or haematological malignancy without prior invasive fungal infection |
| No dehydration requiring IV fluids | 3 | No clinical dehydration requiring intravenous fluid resuscitation |
| Outpatient status at fever onset | 3 | Fever developed while patient was an outpatient |
| Age < 60 years | 2 | Patient is younger than 60 years at time of FN episode |
| Maximum score | 26 | Score ≥21: Low risk; Score <21: High risk |
What is febrile neutropenia?
Febrile neutropenia is defined as a temperature above 38.3°C once or above 38.0°C sustained for one hour, occurring in a patient with an absolute neutrophil count (ANC) below 500 cells/µL or expected to fall below 500 cells/µL within 48 hours. It is a medical emergency in cancer patients and requires immediate evaluation and empirical antibiotic therapy.
What MASCC score is considered low risk?
In the context of Febrile Neutropenia Risk, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of health and medical practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
What antibiotics are used for low-risk febrile neutropenia?
In the context of Febrile Neutropenia Risk, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of health and medical practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
Can G-CSF prophylaxis prevent febrile neutropenia?
In the context of Febrile Neutropenia Risk, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of health and medical practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
What is the most common cause of febrile neutropenia?
Febrile Neutropenia Risk is a specialized calculation tool designed to help users compute and analyze key metrics in the health and medical domain. It takes specific numeric inputs — typically drawn from real-world data such as measurements, rates, or quantities — and applies a validated mathematical formula to produce actionable results. The tool is valuable because it eliminates manual calculation errors, provides instant feedback when exploring different scenarios, and serves as both a decision-support instrument for professionals and a learning aid for students studying the underlying principles.
What is the CISNE score and how does it differ from MASCC?
The Clinical Index of Stable Febrile Neutropenia (CISNE) is an alternative validated risk stratification tool, specifically derived for patients with solid tumours and apparently stable FN. CISNE uses different variables including ECOG performance status, chronic cardiovascular disease, strict monocytes criterion, and presence of stress hyperglycaemia. Some studies suggest CISNE outperforms MASCC for solid tumour populations specifically.
How long should antibiotics be given for febrile neutropenia?
Antibiotic duration depends on ANC recovery and defervescence. For low-risk patients, oral antibiotics are continued until afebrile for 48 hours and ANC >500 cells/µL. For high-risk patients on IV antibiotics, treatment continues until ANC recovery and sustained apyrexia. Minimum durations are typically 4–7 days even if early clinical improvement occurs.
Should antifungal therapy be added empirically?
Use Febrile Neutropenia Risk whenever you need a reliable, reproducible calculation for decision-making, planning, comparison, or verification. Common triggers include evaluating a new opportunity, comparing two or more alternatives, checking whether a quoted figure is reasonable, preparing documentation that requires precise numbers, or monitoring changes over time. In professional settings, recalculating regularly — especially when key inputs change — ensures that decisions are based on current data rather than outdated estimates. Students should use the tool after attempting manual calculation to verify their understanding of the formula.
Pro Tip
Always take at least two sets of blood cultures (peripheral and from each lumen of any central venous catheter) BEFORE administering the first antibiotic dose. The window for positive cultures closes rapidly once antibiotics are started, and pathogen identification is essential for rational antibiotic de-escalation and duration decisions.
Did you know?
The MASCC risk index was derived from a prospective study of over 1,000 FN episodes across 14 centres in 11 countries — making it one of the most internationally representative FN datasets ever assembled. The study was specifically designed to challenge the then-universal practice of hospitalising all FN patients, proving that a substantial proportion could be managed safely at home and revolutionising FN care worldwide.
References
- ›Klastersky J et al. The Multinational Association for Supportive Care in Cancer risk index. J Clin Oncol 2000.
- ›Freifeld AG et al. IDSA Clinical Practice Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients. Clin Infect Dis 2011.
- ›ASCO Clinical Practice Guideline: Recommendations for the Use of WBC Growth Factors. J Clin Oncol 2015.
- ›ESMO Clinical Practice Guidelines: Febrile Neutropenia. Ann Oncol 2016.
- ›MDCalc — MASCC Risk Index for Febrile Neutropenia